4:12 PM
 | 
Dec 23, 2013
 |  BC Extra  |  Clinical News

Can-Fite's CF101 meets in Phase IIb RA trial

Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF) said twice-daily oral CF101 met the primary endpoint of improving ACR20 response rate at week 12 vs. placebo in a Phase IIb trial to treat rheumatoid arthritis (49% vs. 25%, p=0.035)....

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >